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(8). Incidental renal masses tend to be 
smaller than symptomatic masses (9), but 
they are not harmless. In a study of nearly 
4,000 patients with incidental renal tumors, 
14.4% died of cancer over an average 4-year 
follow-up, despite treatment (10).
Most solid renal masses are presumed to 
be malignant and excised. There is therefore 
relatively little data on the natural history of 
untreated masses. However, a meta-analysis 
covering 234 patients that did not undergo 
immediate surgery found a mean tumor size 
at diagnosis of 2.6 cm and a mean growth 
rate of 0.28 cm per year (11). A subsequent 
study of 106 patients found that one-third 
of masses did not grow over a 25-month 
follow-up (12), while in a prospective study 
of 82 patients undergoing active surveil-
lance for a median duration of 3 years, most 
masses grew, but 10% were stable, and 5% 
regressed (13). It is unknown whether these 
were benign masses. Larger masses gener-
ally grow faster than smaller masses, and 
bigger tumor size predicts a shorter average 
survival (10, 14). With slow initial growth 
rates, it may take several years for a mass 
to develop to a size that causes complica-
tions. Nevertheless, a comparison of the 
prevalence of incidental renal masses and 
of symptomatic renal cancer suggests that 
most incidental masses will progress to clin-
ical disease, with a sojourn time of between 
3.7 and 5.8 years (15). Screening aims to 
identify a cancer early, i.e., while the tumor 
is small, localized, and treatable. The natural 
history of small masses suggests that this 
aim can be achieved, as most grow slowly.
Screening programs are most efficient 
if they target high-risk populations. The 
incidence of renal cancer varies with gen-
der, age, and ethnicity. The incidence is 
roughly twice as high in men as in women 
(2), increases with age (16), and is higher 
in African Americans and lowest in Asian 
Americans (17). A number of lifestyle and 
Renal cancer kills over 26,000 people per 
year in Europe and 13,000 in the United 
States (1, 2). If identified before metastatic 
spread, kidney cancer is usually surgically 
curable (3), whereas the median survival 
with disseminated cancer is only 2 years (4). 
Turney et al. proposed in 2006 that a screen-
ing program using ultrasound could have a 
major impact on renal cancer mortality (5). 
The suggestion was criticized on the basis 
that the natural history of renal cancer was 
poorly understood, and that the treatment 
of renal masses would not be of net benefit 
in older populations (6). In the past 7 years, 
however, the natural history and epidemi-
ology of renal cancer have become much 
clearer. Moreover, nephron-sparing surgery 
and minimally invasive ablation are now 
better established (7), changing the cost-
benefit ratio for treatment in older popu-
lations. These developments mean that a 
targeted renal cancer screening program is 
now a real option. The evidence for such 
a screening program is presented in three 
parts: first, an update on the natural history 
and risk factors; second, a calculation of the 
benefits and harms of screening in differ-
ent populations, and third, lessons from 
other cancer screening programs. Finally, a 
clinical algorithm to aid with screening and 
treatment choices is presented.
Diagnosis of renal cancer is made by 
imaging of the kidneys: a solid mass on 
ultrasound scan (USS) or an enhancing 
mass on computed tomography (CT) is 
considered malignant until proven other-
wise. Histological examination shows that 
approximately 85% of masses are malignant 
(8). Historically, imaging of the kidneys was 
performed in symptomatic patients. With 
the increasing use of imaging for other 
abdominal complaints, however, many 
renal masses are identified as incidental 
findings. These “incidentalomas” now 
account for the majority of renal  cancers 
medical factors can increase the risk of 
kidney cancer. In particular, smoking (18), 
obesity (19), hypertension (20, 21), family 
history (22), multi-parity for women (23), 
end-stage renal disease (24), and exposure 
to carcinogens (2) are recognized risk fac-
tors. Heavy smoking, severe hypertension, 
and morbid obesity each double the risk of 
renal cancer, while a family history increases 
the risk fourfold. Certain segments of the 
population are therefore at increased risk. 
For example, an obese, hypertensive man 
who smoked heavily would be 8 times as 
likely to have kidney cancer as a normoten-
sive, non-smoking, thin man, and 16 times 
as likely as a normotensive non-smoking 
thin woman. The identification of these risk 
factors means that screening can be targeted 
at high-risk populations.
It is clearly possible to identify renal 
masses before they cause symptoms: these 
are incidentalomas. A retrospective analysis 
of all the cases of kidney cancer in Iceland 
found that incidental tumors were on average 
2.6 cm smaller and of lower stage and grade 
than symptomatic tumors (9). This supports 
the hypothesis that imaging in asymptomatic 
patients can identify renal masses earlier, 
when they are smaller. CT can identify renal 
masses of less than 3 cm more than 90% of 
the time, compared to 67–79% of the time for 
USS (25). If a renal mass is identified early, 
treatment is usually curative. The 5-year 
survival with localized renal cancer is 91% 
but with distant spread only 11% (16); this 
reflects both the slow natural progress of the 
disease and the effectiveness of surgical treat-
ment of small tumors. The tools to identify 
at risk populations, to diagnose renal cancer 
early, and to treat early renal cancer effectively 
are therefore all currently available.
The hoped-for benefit of a screening pro-
gram for renal cancer would be a reduction 
in cancer mortality. The potential harms 
include the cost of screening, the direct 
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harm from the screening  investigations, 
and the harm from unnecessary procedures 
like biopsies or surgery in individuals with 
a false-diagnosis or an overdiagnosis (i.e., 
a positive screen in a patient with a cancer 
that would not have caused symptoms in 
their lifetime). The benefit of treatment can 
be calculated based on disease incidence, 
screening accuracy, and current surgical 
outcomes compared to the natural history 
of untreated disease. The harm of over-
treatment can similarly be estimated from 
the complication rates of treatment and 
the number of cases of overdiagnosis or 
false-diagnosis.
The likelihood of finding a solid renal 
mass depends on the population and the 
screening modality. Thus, in a high-risk 
population like obese male smokers in 
their 60s, with an incidence of renal cancer 
of approximately 400 per 100,000 person-
years, a 100% sensitive screening tool would 
identify a case of renal cancer in every 250 
individuals. CT, with 90% sensitivity, could 
be expected to identify a case of renal can-
cer in every 278 individuals. The natural 
history of untreated renal masses indicates 
that about a quarter of masses identified 
do not measurably grow (this will prob-
ably include many benign tumors, as well 
as non-cancerous masses from false-diag-
nosis). In a patient with a life-expectancy of 
several years, we can therefore expect about 
three quarters of asymptomatic masses to 
progress to overt disease, in other words, 
the false-diagnosis and overdiagnosis rates 
combined would be about 25%. CT screen-
ing would thus be expected to identify 
one malignant mass for every 371 people 
screened.
Surgical treatment of small renal tumors 
offers a 5-year cancer specific mortality-free 
rate of 97.5% (26). The risks of intervention 
are small but not negligible: 2–4% of cases 
require reoperation for complications (27). 
Nonetheless, the benefits from surgery could 
be very large. Assuming that clinical renal 
cancer develops from small renal masses, 
then treatment of all small renal masses 
would reduce mortality from kidney cancer 
by 97.5% at 5 years, saving over 25,000 lives 
per year in the EU, and over 12,000 in the 
United States. In practice, it may be  possible 
to screen a subsection of the population 
with an imperfectly sensitive test like CT. 
For example, screening men at age 60, 65, 
and 70 would target a demographic at high 
risk of developing clinical kidney cancer. 
Given the slow average growth rate of renal 
masses, 5-yearly screening would be likely 
to pick up most cancers at a treatable stage. 
Extrapolating from age-specific data, screen-
ing of men aged 60 and above could identify 
92% of fatal renal cancers in men, and 55% 
of fatal renal cancers overall (28). Screening 
men over 60 with CT (90% sensitive), and 
offering them all surgery would result in the 
detection of 83% of otherwise fatal renal 
cancers in men, and a cure for 97.5% of these 
men. Although 2–4% of those undergoing 
surgery could expect a major complication, 
this would still represent a dramatic drop in 
mortality from kidney cancer.
On the other hand, the harm of over-
treatment might outweigh the benefits of 
screening, particularly in populations with 
a reduced life-expectancy (29). For exam-
ple, surgical treatment of renal masses 
Figure 1 | Algorithm for targeted screening and treatment of renal 
cancer. (A) Patients are assigned a score based on known risk factors for renal 
cancer. (B) A score greater than five leads to screening by ultrasound or CT 
scan, while a score less than five does not lead to screening. A small renal 
mass identified on screening can be further characterized by biopsy or repeat 
scan before treatement, while a large mass identified on screening leads 
directly to treatment. Treatment of identified masses will be influenced by 
patient comorbidities and patient choice; options include active surveillance, 
surgical excision, or ablation of the mass. USS, ultrasound scan; CT, computed 
tomography.
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 insensitive, such as chest X-ray, or that 
detected advanced disease and so gave no 
stage-shift at diagnosis (for ovarian cancer). 
The screening tools for renal cancer on the 
other hand have high sensitivity and speci-
ficity and also allow detection of inciden-
talomas at an early stage (25, 36). Screening 
for  prostate cancer was furthermore ham-
pered by overdiagnosis (37). Careful selec-
tion of the population to be screened could 
 minimize this risk, for example by  restricting 
screening to  individuals with a predicted 
life-expectancy greater than 5 years.
In the absence of a large randomized 
controlled trial of renal cancer screening, 
the potential benefits can be assessed using 
the Wilson–Jungner criteria (38). Renal 
cancer is an important medical problem; its 
natural history is increasingly understood; it 
is detectable at an early stage using accept-
able technology, and the benefits of early 
treatment outweigh the harms. To optimize 
the screening for kidney cancer, a clini-
cal algorithm can be used to select target 
populations and aid in treatment decisions 
(Figure 1). Mounting evidence points to the 
time being ripe for the implementation of a 
renal cancer screening program that could 
save tens of thousands of lives per year.
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